PTC Therapeutics
PTCT
132 hedge funds and large institutions have $1.47B invested in PTC Therapeutics in 2014 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 58 increasing their positions, 23 reducing their positions, and 5 closing their positions.
660% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 5
152% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 23
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
37% more capital invested
Capital invested by funds: $1.07B → $1.47B (+$395M)
33% more funds holding
Funds holding: 99 → 132 (+33)
53% less call options, than puts
Call options by funds: $1.5M | Put options by funds: $3.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$54.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.8M |
| 3 |
CCI
Columbus Circle Investors
|
+$26.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.5M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$34.3M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$16.7M |
| 3 |
Millennium Management
New York
|
-$14.1M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$8.24M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.7M |
PTCT Hedge Fund Activity: Q4 2014 in Review
132 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2014, worth a combined $1.47B — up 37% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new PTCT positions and 5 closed out — a net gain of 33 holders — while 58 added to existing stakes and 23 trimmed.
The largest buyer was BB Biotech, opening a new position worth an estimated $54.1M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $34.3M.
- 132 institutional investors held PTC Therapeutics (PTCT) as of Q4 2014, up from 99 in Q3 2014.
- Funds reported $1.47B of PTC Therapeutics stock for Q4 2014, up 37% quarter-over-quarter.
- 38 funds opened new PTC Therapeutics positions in Q4 2014 and 5 closed out, a net change of +33 holders.
- The largest PTC Therapeutics buyer in Q4 2014 was BB Biotech, an estimated $54.1M added.
- The largest PTC Therapeutics seller in Q4 2014 was Bain Capital Public Equity Management, an estimated $34.3M sold.
Based on aggregated 13F filings for Q4 2014.